AliveCor , the leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced Jacqueline Shreibati, MD, MS, FACC, as Chief Medical Officer of the company. In her new role, Dr. Shreibati will lead AliveCor's medical roadmap, developing innovative products that employ digital intelligence to improve heart care and to help save lives.
Dr. Shreibati is a board-certified cardiologist. She completed her medical school, Internal Medicine residency, and Cardiology fellowship all at Stanford University. Dr. Shreibati has a Master's degree in health services research, a field that studies how financial systems, organizational structures, health technologies and personal behaviors affect health care access, quality and cost. Dr. Shreibati formerly served as the company's Vice President of Medical Affairs.
“Dr. Shreibati combines extensive scientific expertise with a deep practical understanding of the day-to-day needs of patients, physicians, payers and regulators. She is fluent in the application of artificial intelligence and machine learning, and how these sciences can influence the future of medicine.” said Ira Bahr, CEO at AliveCor. “Over time, Dr. Shreibati will be a leading voice in our march to greater accessibility, affordability and efficacy in cardiology – all through the use of new digital technologies.”
“I'm honored to be appointed as AliveCor's Chief Medical Officer,” said Dr. Shreibati. “This role is the culmination of my clinical, research and industry experience, and personal areas of passion. It allows me to influence the health outcomes of millions of people and to potentially change the way in which cardiology services are delivered.”
AliveCor's founder, Dr. Dave Albert, previously the company's Chief Medical Officer, will remain an integral part of the leadership team by focusing on the development of new products and services.
“Through our work over the last decade, AliveCor has reached many milestones, including being one of the first and most clinically-validated digital health innovators,” said Dr. Albert. “From being honored as Fast Company's most innovative companies several years in a row to receiving FDA breakthrough device recognition for our hyperkalemia test, we've made incredible progress for the industry. There is still an immense amount of work we can do to make heart care more intelligent, more convenient and less expensive, and I'm excited to partner with Dr. Shreibati to continue to expand care and grow AliveCor as a company.”
About AliveCor
AliveCor, Inc. is pioneering the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is the most clinically validated mobile ECG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an ECG. Kardia is the first A.I. enabled platform to help clinicians manage patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia and one that leads to a five times greater risk of stroke. KardiaBand is the first FDA-cleared medical device accessory for Apple Watch. AliveCor was named the No.1 artificial intelligence company on Fast Company’s Top 50 Most Innovative Companies , in addition to ranking 20th overall in an evaluation of thousands of companies worldwide. AliveCor is a privately-held company headquartered in Mountain View, Calif. For more information, visit alivecor.com .